

Table S1: Summary of quality assessment based on the Newcastle-Ottawa quality assessment scale for **cohort studies on viral load and duration of detection** [1].

Study	Design	Study quality						Overall quality (sum)	Reference
		S1	S2	S3	C1	O1	O3		
Abu-Raddad 2022	Cohort study	*	*	*	*	*	n. a. [#]	5 [#]	[2]
Muhsen 2022	Prospective cohort study	-	*	-	*	*	n. a. [#]	3 [#]	[3]
Regev-Yochay 2021	Prospective cohort study	-	*	*	*	*	n. a. [#]	4 [#]	[4]
Pouwels 2021	Cohort study	*	*	*	**	*	n. a. [#]	6 [#]	[5]
Shrotri 2021	Prospective cohort study	-	*	*	*	*	n. a. [#]	4 [#]	[6]
Chia 2022	Retrospective cohort study	*	-	*	*	-	-	3	[7]
Elliott 2021	Prospective cohort study	*	*	-	*	*	n. a. [#]	4 [#]	[8]
Jung 2022	Cohort study	-	*	*	*	*	*	5	[9]
Koh 2022	Retrospective cohort study	-	*	*	*	-	-	3	[10]
Sriraman 2022	Prospective cohort study	-	*	*	-	*	*	4	[11]
Thompson 2022	Prospective cohort study	-	*	*	*	*	*	5	[12]
Garcia-Knight 2022	Cohort study	-	*	*	*	*	*	5	[13]
Thompson 2021	Prospective cohort study	*	*	*	*	*	-	5	[14]
Kissler 2021	Cohort study	-	*		**	*	*	5	[15]
Maier 2022	Prospective cohort study	*	*	*	*	*	*	6	[16]
Tian 2022	Retrospective cohort Study	-	*	*	*	*	-	3	[17]
Kang 2022	Cohort study	-	*	*	*	*	*	5	[18]
Ke 2022	Cohort study	-	*		*	*	*	4	[19]

[#] Data of interest for this review was not obtained longitudinally, the maximum number of attainable points was therefore 6 instead of 7

Selection

S1: Representativeness of the exposed cohort (maximum: *)

S2: Selection of the non-exposed cohort (maximum: *)

S3: Ascertainment of exposure (confirmation of vaccination or prior infection, respectively) (maximum: *)

Comparability

C1: Comparability of cohorts on the basis of the design or analysis (maximum: **)

Outcome

O1: Assessment of outcome (always viral load) (maximum: ✱)

O3: Adequacy of follow up of cohorts (maximum: ✱)

Additional explanation: The Newcastle-Ottawa quality assessment scale typically includes an assessment that outcome of interest was not present at start of study (selection, point 4) an assessment if the follow-up was long enough for outcomes to occur (outcome, point 2). Both quality parameters are not relevant for the question of the review because differences in viral load were evaluated (viral load as the main outcome was always present at the beginning) or differences regarding the duration of viral detection were assessed (viral load as the outcome was again present at the beginning).

References

- [1] Gierisch JM, Beadles C, Shapiro A, et al. NEWCASTLE-OTTAWA SCALE CODING MANUAL FOR COHORT STUDIES. In: Health Disparities in Quality Indicators of Healthcare Among Adults with Mental Illness. Department of Veterans Affairs (US); 2014: Appendix B
- [2] Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. *Nat Commun* 2022; 13: 532. doi:10.1038/S41467-022-28199-7
- [3] Muhsen K, Maimon N, Mizrahi A, et al. Effectiveness of BNT162b2 mRNA COVID-19 vaccine against acquisitions of SARS-CoV-2 among health care workers in long-term care facilities: a prospective cohort study. *Clin Infect Dis* 2022; 75: e755–e763. doi:10.1093/CID/CIAB918
- [4] Regev-Yochay G, Amit S, Bergwerk M, et al. Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel. *Lancet Reg Heal - Eur* 2021; 7: 100150. doi:10.1016/J.LANEPE.2021.100150
- [5] Pouwels KB, Pritchard E, Matthews PC, et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. *Nat Med* 2021; 27: 2127–2135. doi:10.1038/S41591-021-01548-7
- [6] Shrotri M, Krutikov M, Palmer T, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. *Lancet Infect Dis* 2021; 21: 1529–1538. doi:10.1016/S1473-3099(21)00289-9
- [7] Chia PY, Ong SWX, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. *Clin Microbiol Infect* 2022; 28: 612.e1-612.e7. doi:10.1016/J.CMI.2021.11.010
- [8] Elliott P, Haw D, Wang H, et al. Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. *Science* 2021; 374: eabl9551. doi:10.1126/SCIENCE.ABL9551
- [9] Jung J, Kim JY, Park H, et al. Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals. *JAMA Netw Open* 2022; 5: e2213606. doi:10.1001/JAMANETWORKOPEN.2022.13606
- [10] Koh T, Ooi XY, Vasoo S, et al. Impact of Variant of Concern and Vaccination Status on COVID-

19 Infection Virological Dynamics in End Stage Kidney Disease Patients Receiving Haemodialysis. *Nephrology* 2022; 27: 804–809. doi:10.1111/NEP.14084

- [11] Sriraman K, Shaikh A, Vaswani S, et al. Impact of COVID-19 vaccination on transmission risk of breakthrough infections: Lessons from adapted N95 mask sampling for emerging variants and interventions. *J Med Virol* 2022; 28188. doi:10.1002/JMV.28188
- [12] Thompson MG, Yoon SK, Naleway AL, et al. Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers. *JAMA* 2022; 328: 1523–1533. doi:10.1001/JAMA.2022.18550
- [13] Garcia-Knight M, Anglin K, Tassetto M, et al. Infectious viral shedding of SARS-CoV-2 Delta following vaccination: A longitudinal cohort study. *PLoS Pathog* 2022; 18: e1010802. doi:10.1371/JOURNAL.PPAT.1010802
- [14] Thompson MG, Burgess JL, Naleway AL, et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. *N Engl J Med* 2021; 385: 320–329. doi:10.1056/NEJMOA2107058
- [15] Kissler SM, Fauver JR, Mack C, et al. Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons. *N Engl J Med* 2021; 385: 2489–2491. doi:10.1056/NEJMc2102507
- [16] Maier HE, Plazaola M, Lopez R, et al. SARS-CoV-2 infection-induced immunity and the duration of viral shedding: Results from a Nicaraguan household cohort study. *Influenza Other Respi Viruses* 2022; 17: e13074. doi:10.1111/IRV.13074
- [17] Tian X, Zhang Y, Wang W, et al. The impacts of vaccination status and host factors during early infection on SARS-CoV-2 persistence:a retrospective single-center cohort study. *Int Immunopharmacol* 2022; 114: 109534. doi:10.1016/J.INTIMP.2022.109534
- [18] Kang SW, Kim JY, Park H, et al. Comparison of outward transmission potential between vaccinated and partially vaccinated or unvaccinated individuals with the SARS-CoV-2 delta variant infection. *J Infect* 2022; 85: e69. doi:10.1016/J.JINF.2022.06.002
- [19] Ke R, Martinez PP, Smith RL, et al. Longitudinal Analysis of SARS-CoV-2 Vaccine Breakthrough Infections Reveals Limited Infectious Virus Shedding and Restricted Tissue Distribution. *Open Forum Infect Dis* 2022; 9: ofac192. doi:10.1093/OFID/OFAC192